LEUVEN, Belgium, March 11 /PRNewswire/ -- KFH has today announced the European launch of KFH Novo, a new and innovative product to address the major problem of chronic wounds. KFH Novo is a patented, high-tech medical device that is non-invasive, and can be used without interfering with standard conventional therapy.
It utilizes Bio-Electric Stimulation Therapy (BEST) to deliver extremely low levels of current to wounds. The electrodes are placed a distance away from the wounds, completely outside the normal treatment areas.
This therapy has been shown to heal different types of chronic wounds such as venous ulcers, pressure sores and diabetic ulcers, even where they have been open for longer than a year.
Prof. Raf Meesen from the Limburg University College in Belgium confirmed: "The initial results with KFH Novo appear to be very promising. Some wounds that we could not get closed with standard treatments healed completely when KFH Novo was applied".
BEST enhances tissue healing
BEST works by enhancing the physiological processes of wound healing, documented effects include
- Attracting the right cells to the wound area e.g. keratinocytes (cells which make up 90% of the outer layer of skin called the epidermis)
- Stimulating fibroblast cells to activate wound healing
- Increasing the production of ATP, providing energy to restart tissue healing
- Increasing the blood and oxygen supply to wound beds
The CEO of KFH, Dr Henk Snyman, said: "Chronic wounds remain a major clinical challenge and represents a big burden to healthcare systems everywhere, both in terms of human and financial resources. KFH Novo is a very cost-effective solution, and we expect significant demand from wound care professionals."
"There is a great deal of interest from the medical community," added Marc Dauwe, Director of Medical Affairs. "KFH is looking for specialist sales partners and we would like to invite interested distributors to contact us directly."
Notes to Editors:
KFH is a young healthcare company, developing its own pipeline of proprietary products. It utilizes a technology platform called BEST (Bio-Electric Stimulation Therapy), from which unique products are developed. For more information see http://www.kfhealth.com/novo
Contact: Marc Dauwe, Kingfisher Healthcare, tel: +32-16-39-78-34, Email firstname.lastname@example.org; Kingfisher Healthcare, Interleuvenlaan 62, 3001, Leuven, Belgium